论文部分内容阅读
目的观察心脉通胶囊联合福辛普利治疗原发性高血压的临床疗效。方法选取2013年1月—2014年8月在新郑市人民医院确诊的原发性高血压患者120例,采用随机随机数字表法分为观察组和对照组,各60例。对照组患者单纯使用福辛普利治疗,观察组患者使用心脉通胶囊联合福辛普利治疗,比较两组患者治疗前后血压、血脂、血流变学指标。结果两组治疗前收缩压、舒张压比较,差异均无统计学意义(P>0.05);观察组治疗后收缩压、舒张压均低于对照组(P<0.05)。两组患者治疗前血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平比较,差异均无统计学意义(P>0.05);观察组患者治疗后血清TC、TG、LDL-C水平均低于对照组,血清HDL-C水平高于对照组(P<0.05)。两组治疗前全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原比较,差异均无统计学意义(P>0.05);观察组患者治疗后全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原均低于对照组(P<0.05)。结论心脉通胶囊联合福辛普利治疗原发性高血压的疗效优于单一使用福辛普利,同时可以稳定控制患者血压,改善血脂状况,优化血流变学指标。
Objective To observe the clinical effect of Xinmaitong capsule combined with fosinopril on essential hypertension. Methods 120 patients with essential hypertension diagnosed in Xinzheng City People’s Hospital from January 2013 to August 2014 were randomly divided into observation group and control group with 60 cases in each group. Patients in the control group were treated with fosinopril alone. Patients in the observation group were treated with xinmaitong capsule combined with fosinopril. Blood pressure, blood lipid and hemorheology were compared between the two groups before and after treatment. Results There was no significant difference in systolic blood pressure and diastolic blood pressure between the two groups before treatment (P> 0.05). The systolic blood pressure and diastolic blood pressure were lower in the observation group after treatment than those in the control group (P <0.05). There was no significant difference in serum TC, TG, LDL-C and HDL-C before treatment in both groups (P> 0.05) P> 0.05). The levels of TC, TG and LDL-C in the observation group were lower than those in the control group, and the serum HDL-C level was higher than that in the control group (P <0.05). There was no significant difference between the two groups before treatment in whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and fibrinogen (P> 0.05). In the observation group, the whole blood high shear viscosity, Cut viscosity, plasma viscosity, fibrinogen were lower than the control group (P <0.05). Conclusion Xintmai capsule combined with fosinopril is superior to fosinopril alone in the treatment of essential hypertension. At the same time, it can control blood pressure, improve blood lipid status and optimize hemorrheological parameters.